2014 Archived Content

Engineering Bispecific Antibodies


Day 1 | Day 2 | Download Brochure | Speaker Bios 

Scientific Advisory Board
Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG
Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab, LLC
 

 

THURSDAY, MAY 8

 

OPENING KEYNOTE SESSION 

1:30 pm Chairperson's Opening Remarks

Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab LLC

1:40 Bispecific and Bifunctional Antibodies for Modulating Immune Responses in Cancer Therapy

Roland KontermannRoland E. Kontermann, Ph.D., Mildred Scheel Professor, Biomedical Engineering, University of Stuttgart

Bispecific and bifunctional antibody fusion proteins allow a targeted delivery and modulation of immunological responses, e.g. by retargeting effector cells of the immune system and activation of immunostimulatory or immunoregulatory signaling pathways. General strategies and new developments in the field will be presented.

2:10 Pathways with FDA: Insight into Regulation, Cocktails vs. Bispecific Antibodies

Kathleen ClouseKathleen A. Clouse, Ph.D., Director, Monoclonal Antibodies, FDA/CDER/OPS/OBP/DMA





2:40 High-Throughput Bispecifics Generation and Testing

Maria WendtMaria Wendt, Ph.D., Senior Scientific Consultant, Biologics, Genedata

The need for systematic evaluation of large panels of multi-specific antibodies poses new throughput bottlenecks for antibody engineering. Multiple next-generation antibody formats must be tested (e.g. bi- and multi-specifics, KinH, Fab-scFv, IgG-scFv, DVD-Ig, tandem-scFv-Fc), including all parametric variants (e.g. linkers, V-domain order, Fc), which creates huge combinatorial complexity. We present a new technology platform that allows for the systematic design and cloning of large numbers of novel molecules and automates downstream expression, purification, and characterization processes, which substantially increases throughput.

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing


Developability Assays 

3:55 Chairperson's Remarks

Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab LLC

4:00 Novel Engineering Solutions to the “Common Light Chain Problem” Give Rise to Potent Bispecifics with Favorable Developability Profiles

Robert MabryRobert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab LLC

We report here the engineering of multiple VHs that pair with a single light chain against three targets with unrelated epitopes. Bispecific constructs were generated with a common light chain that bind to each target with low picomolar affinities and exhibit favorable biophysical properties similar to benchmarks established by traditional mAbs.

4:30 Engineering Antibody Fc and Fab Regions for Generation of Bispecific and Monovalent Antibodies

GunaKannanGuna Kannan, Ph.D., Principal Scientist and Group Leader, Biologics Optimization, Amgen, Inc.

We have modified the CH3 domain of the Fc region and the light and heavy chain interface of the Fab with targeted mutations in order to generate bispecific antibodies. The engineered bispecific antibodies have desirable in vivo and in vitro stabilities. The presentation will cover the engineering aspects as well as various strategies used to mitigate the issues encountered during the screening and production stages.

5:00 Close of Day


RECOMMENDED THURSDAY DINNER SHORT COURSE*

Antibody-Based Cancer Immunotherapy - Detailed Agenda 

*Separate registration required


Day 1 | Day 2 | Download Brochure | Speaker Bios